The Sonnerie VC Glossary defines 62 terms across drug modalities, FDA and device regulation, clinical development, and venture financing, for founders and investors in healthcare and life sciences.

Knowledge Hub · Reference

Glossary.

62 terms across drug modalities, FDA and device regulation, clinical development, medical devices, and venture financing. Defined plainly, and factually, for founders and investors in healthcare and life sciences.

Drug Modalities and Technology Regulatory and Clinical Development Medical Devices Venture and Company Formation Market and Reimbursement

Drug Modalities and Technology

Small Molecule
A small molecule is a chemically synthesized compound, typically under roughly 900 daltons in molecular weight, small enough to cross cell membranes and often the gut wall, which allows many to be formulated as oral pills. Small molecules can act on targets inside cells, including enzymes and receptors, and are manufactured through chemical synthesis rather than living systems. Because their structure is well defined, they are generally easier to characterize, manufacture at scale, and copy once patent protection expires, which is why most generic drugs are small molecules. Read more →
Biologic
A biologic is a therapeutic product derived from or produced using living cells or organisms, encompassing proteins, antibodies, vaccines, and cell or gene therapies. Biologics are typically much larger and more structurally complex than small molecules, so they generally cannot survive digestion and are administered by injection or infusion rather than as a pill. Because manufacturing depends on living cell lines and biological processes, biologics are harder to characterize precisely and to reproduce exactly, which is why their generic counterparts are called biosimilars rather than generics. Read more →
Monoclonal Antibody
A monoclonal antibody is a laboratory-produced protein engineered to bind with high specificity to a single target, or epitope, on an antigen such as a cell-surface receptor or circulating molecule. All copies originate from a single cloned cell line, which gives the antibody its uniform, well-defined binding behavior, in contrast to the mixed population of antibodies the immune system naturally produces. Monoclonal antibodies are used across oncology, autoimmune disease, and infectious disease, and can work by blocking a target’s activity, flagging cells for immune destruction, or delivering an attached payload. Read more →
Antibody-Drug Conjugate (ADC)
An antibody-drug conjugate, or ADC, links a monoclonal antibody to a cytotoxic small-molecule payload through a chemical linker, combining the antibody’s targeting specificity with the payload’s cell-killing potency. The antibody portion binds a target expressed preferentially on diseased cells, such as a tumor antigen, and after the complex is internalized, the linker releases the payload inside the cell. The design is intended to concentrate a potent drug at diseased tissue while limiting exposure to healthy tissue, though linker stability and target expression on normal cells both affect how well that selectivity holds in practice. Read more →
Bispecific Antibody
A bispecific antibody is an engineered antibody constructed to bind two distinct targets or epitopes simultaneously, rather than the single target a conventional monoclonal antibody recognizes. A common design binds a tumor antigen with one arm and a receptor on an immune cell, such as a T cell, with the other, bringing the two cells into physical proximity to trigger an immune attack on the tumor. Bispecifics can also be designed to block two disease pathways at once, and their added structural complexity generally makes them harder to manufacture than standard monoclonal antibodies. Read more →
CAR-T Cell Therapy
CAR-T cell therapy is a form of cell therapy in which a patient’s own T cells, or in some approaches donor T cells, are genetically engineered to express a chimeric antigen receptor, or CAR, that redirects the cells to recognize and kill cells bearing a specific target antigen. The engineered cells are expanded outside the body and then infused back into the patient, where they can proliferate and persist. CAR-T therapies have shown durable responses in certain blood cancers, and they carry distinctive risks, including cytokine release syndrome and neurotoxicity, that require specialized monitoring after infusion. Read more →
Gene Therapy
Gene therapy treats or prevents disease by introducing, correcting, silencing, or replacing genetic material within a patient’s cells, often using a modified viral vector, such as an adeno-associated virus, to deliver the genetic payload. Approaches vary widely, from adding a functional copy of a missing or defective gene, to gene editing techniques that alter an existing sequence directly. Because the intended effect can be a single durable or permanent correction rather than a repeated dose, gene therapies raise distinct questions around long-term safety monitoring and durability of response. Read more →
RNA Therapeutics
RNA therapeutics are a class of medicines that act on or through ribonucleic acid rather than encoding a protein drug directly, and the category spans several distinct mechanisms. Messenger RNA, or mRNA, therapeutics deliver a synthetic transcript instructing cells to produce a target protein, most familiar from mRNA vaccines. Small interfering RNA, or siRNA, and antisense oligonucleotides instead bind to a specific messenger RNA sequence to degrade it or block its translation, silencing production of a disease-associated protein, and all three approaches rely on chemical modification and delivery technologies, such as lipid nanoparticles, to protect the RNA and get it into target cells. Read more →
Peptide Therapeutic
A peptide therapeutic is a drug made of a short chain of amino acids, generally larger and more complex than a small molecule but smaller and structurally simpler than a full protein biologic. Peptides can be chemically synthesized rather than produced in living cells, yet many still require injection because they are broken down readily in the digestive tract. They are used to mimic or block naturally occurring hormones and signaling molecules, with metabolic disease and endocrinology among the areas where peptide drugs have been most widely applied. Read more →
Checkpoint Inhibitor
A checkpoint inhibitor is a therapeutic, typically a monoclonal antibody, that blocks immune checkpoint proteins, such as PD-1, PD-L1, or CTLA-4, which tumors can exploit to suppress the immune response against them. By blocking these inhibitory signals, checkpoint inhibitors release a brake on T cells, allowing the immune system to recognize and attack cancer cells more effectively. Because the mechanism amplifies immune activity broadly rather than acting on the tumor directly, checkpoint inhibitors carry a distinctive risk of immune-related side effects affecting healthy tissue.
Kinase Inhibitor
A kinase inhibitor is typically a small-molecule drug that blocks the activity of a kinase enzyme, a protein that regulates cell signaling by adding phosphate groups to other proteins. Many cancers depend on a specific mutated or overactive kinase to drive uncontrolled growth, so inhibiting that kinase can slow or stop tumor proliferation, and kinase inhibitors are also used in inflammatory and autoimmune disease. Because closely related kinases share structural similarities, a persistent challenge in developing these drugs is achieving enough selectivity for the intended target to limit off-target effects.
Biosimilar
A biosimilar is a biologic product shown to be highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Because biologics are manufactured in living cells rather than through fixed chemical synthesis, a biosimilar can never be an exact chemical copy the way a generic small-molecule drug is, so approval instead relies on extensive comparative analytical, and often clinical, data. Biosimilars are intended to offer lower-cost alternatives once a reference biologic’s exclusivity period ends, serving a purpose similar to generics but through a distinct regulatory pathway.

Regulatory and Clinical Development

IND (Investigational New Drug application)
An Investigational New Drug application is the submission a sponsor files with the FDA before testing an experimental drug in humans. It contains preclinical safety data, manufacturing information, and the proposed clinical trial protocol, and FDA has 30 days from receipt to raise concerns or place the trial on clinical hold before human dosing may begin. An active IND generally remains in effect throughout the drug’s clinical development, covering Phase 1 through Phase 3 trials, until the sponsor files for marketing approval or withdraws it. Read more →
NDA (New Drug Application)
A New Drug Application is the formal request a sponsor submits to the FDA seeking marketing approval for a new small-molecule drug. It compiles the full record of preclinical and clinical data, including safety and efficacy results from Phase 1 through Phase 3 trials, manufacturing controls, and proposed labeling. FDA review of an NDA culminates in approval, a complete response letter requesting additional information, or non-approval, and the standard review goal is longer than the priority review goal. Read more →
BLA (Biologics License Application)
A Biologics License Application is the submission required to market a biologic product, such as a monoclonal antibody, vaccine, or cell or gene therapy, in the United States. It serves the same approval function as an NDA but is authorized under a different statute, the Public Health Service Act, and is generally reviewed by FDA’s biologics-focused review divisions. Like an NDA, it requires clinical evidence of safety and efficacy along with detailed manufacturing and facility data. Read more →
510(k)
A 510(k) is a premarket submission made to the FDA to demonstrate that a medical device is substantially equivalent to a legally marketed predicate device with similar intended use and technological characteristics. It is the most common pathway for low- to moderate-risk devices and generally does not require new clinical trial data if equivalence can be shown through bench testing or existing literature. Clearance through 510(k) is a lower evidentiary bar than full PMA approval and covers the large majority of devices reaching the US market. Read more →
PMA (Premarket Approval)
Premarket Approval is the FDA’s most rigorous device review pathway, required for higher-risk devices, typically Class III, that support or sustain life, are implanted, or pose significant risk to patients. It requires the sponsor to submit clinical evidence establishing reasonable assurance of safety and effectiveness, an evidentiary standard closer to that used for drug approvals. PMA review is more extensive and time-consuming than 510(k) clearance and can include advisory committee input. Read more →
De Novo pathway
The De Novo pathway allows manufacturers of novel, low- to moderate-risk devices to obtain marketing authorization when no existing predicate device is available for a 510(k) submission. A successful De Novo request creates a new device classification, which can then itself serve as a predicate for later 510(k) submissions from other companies. It offers a route to market for genuinely new device types without requiring the more burdensome PMA process. Read more →
Breakthrough Therapy Designation
Breakthrough Therapy Designation is granted by the FDA to drugs intended for a serious condition when preliminary clinical evidence indicates the drug may show substantial improvement over available therapies on a clinically significant endpoint. It entitles sponsors to more intensive FDA guidance on an efficient development program, including earlier and more frequent interaction with review staff. It is often paired with other expedited programs, such as Priority Review and Accelerated Approval, though it does not change the evidentiary standard for approval. Read more →
Fast Track designation
Fast Track designation is intended for drugs that treat a serious condition and address an unmet medical need. It allows more frequent communication with the FDA during development and permits rolling review, in which completed sections of a marketing application can be submitted and reviewed before the full application is finished. It affects the development and review process rather than the clinical evidence required for approval. Read more →
Priority Review
Priority Review is an FDA designation that shortens the agency’s goal date for acting on a marketing application to about six months, compared with a standard review goal of about ten months. It is granted when the drug, if approved, would represent a significant improvement in safety or effectiveness for a serious condition compared with existing options. Priority Review changes the review timeline, not the standard of evidence required for approval. Read more →
Accelerated Approval
Accelerated Approval allows the FDA to approve a drug for a serious condition based on its effect on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit, rather than waiting for confirmed clinical outcomes. Sponsors receiving Accelerated Approval are required to conduct post-approval confirmatory trials to verify the anticipated benefit, and the FDA can withdraw approval if those trials fail to confirm it or are not completed with due diligence. The pathway is designed to speed patient access to therapies addressing significant unmet need. Read more →
Orphan Drug Designation
Orphan Drug Designation is granted by the FDA to drugs intended to treat rare diseases, generally defined in the United States as conditions affecting a small number of patients, or for which there is no reasonable expectation that development costs will be recovered from US sales. Designation confers incentives including a tax credit for qualified clinical trial costs, a waiver of certain application user fees, and a period of market exclusivity upon approval that is distinct from patent protection. Designation itself is not marketing approval, and the drug must still complete the standard review process. Read more →
Phase 1 trial
A Phase 1 trial is the first stage of testing an investigational drug in humans, typically enrolling a small number of healthy volunteers or, in some disease areas such as oncology, patients with the condition. Its primary goals are to assess safety, tolerability, and pharmacokinetics, and to identify an appropriate dose range for later study. Phase 1 trials are generally not designed or powered to establish efficacy. Read more →
Phase 2 trial
A Phase 2 trial enrolls a larger group of patients who have the condition the drug is intended to treat, with the primary goals of evaluating preliminary efficacy, further characterizing safety, and refining dosing. These trials often explore dose-response relationships and inform the design of the pivotal Phase 3 program. Results at this stage are generally not sufficient on their own to support marketing approval. Read more →
Phase 3 trial
A Phase 3 trial is a large-scale, typically randomized and controlled study intended to confirm efficacy and monitor adverse effects across a broader patient population, often compared against a placebo or an existing standard of care. These pivotal trials generate the primary evidence submitted in an NDA or BLA, and their design is usually agreed upon with regulators in advance. A successful Phase 3 program is typically the last major clinical milestone before a marketing application is filed. Read more →
Companion diagnostic
A companion diagnostic is a test used to identify patients who are likely to benefit from, or be at risk of a serious adverse reaction to, a specific therapeutic product. It is often developed alongside the corresponding drug and reviewed by the FDA in parallel, since its results determine which patients are eligible for that treatment. Companion diagnostics are especially common in oncology, where they detect a biomarker or mutation the targeted therapy is designed to address. Read more →
CLIA
The Clinical Laboratory Improvement Amendments establish federal standards regulating laboratory testing performed on human specimens in the United States, with certification administered primarily through the Centers for Medicare and Medicaid Services. CLIA sets requirements for personnel qualifications, quality control, and proficiency testing based on the complexity of the test performed. A laboratory must hold the appropriate CLIA certification before reporting patient results, regardless of whether the FDA has separately reviewed the underlying test. Read more →
Laboratory-developed test (LDT)
A laboratory-developed test is a diagnostic test designed, manufactured, and performed within a single certified laboratory rather than sold as a kit to other facilities. LDTs have historically operated primarily under CLIA laboratory quality oversight rather than FDA premarket device review, though the scope of FDA oversight of LDTs has been an evolving area of regulatory policy. They are widely used for specialized or lower-volume tests, including many genetic and other advanced assays offered by academic and reference laboratories. Read more →

Medical Devices

Class I device
The FDA risk category for devices considered to pose the lowest risk to patients, such as bandages, hand-held surgical instruments, and non-electric wheelchairs. Most Class I devices are subject only to general controls, meaning establishment registration, device listing, labeling requirements, and adherence to good manufacturing practice, and the large majority are exempt from premarket notification entirely. Read more →
Class II device
The FDA risk category for moderate-risk devices, such as infusion pumps and many diagnostic imaging systems, where general controls alone are not sufficient to provide reasonable assurance of safety and effectiveness. These devices are also subject to special controls, which can include performance standards, specific labeling requirements, or postmarket surveillance, and most require 510(k) premarket notification before marketing. Read more →
Class III device
The FDA’s highest risk category, generally covering devices that are life-sustaining, life-supporting, implantable, or that present a significant risk of illness or injury, such as implantable pacemakers and prosthetic heart valves. These devices typically require premarket approval, the most rigorous device pathway, which demands valid scientific evidence, often including clinical trial data, of safety and effectiveness before marketing. Read more →
Predicate device
A legally marketed device to which a manufacturer compares a new device in a 510(k) submission. A device can serve as a predicate if it was in commercial distribution before the FDA’s medical device authorities took effect in 1976, if it was already found substantially equivalent through a prior 510(k), if it was reclassified into a lower risk category, or if it received marketing authorization through the De Novo pathway. The comparison must show the new device has the same intended use and, generally, the same technological characteristics as the predicate, or that any differences do not raise new questions of safety and effectiveness. Read more →
510(k) clearance
A premarket notification pathway, named for the relevant section of the Food, Drug, and Cosmetic Act, in which a manufacturer demonstrates that a new device is substantially equivalent to a legally marketed predicate device. Because the goal is equivalence rather than independent proof of safety and effectiveness, this pathway is generally faster and less costly than premarket approval, and it covers most Class II devices along with some Class I and Class III devices. Read more →
PMA approval for devices
Premarket approval, or PMA, is the FDA’s most stringent device review pathway, required for most Class III devices that lack a valid predicate. Rather than showing equivalence to an existing device, the manufacturer must submit valid scientific evidence, typically including data from clinical investigations, sufficient to provide reasonable assurance that the device is safe and effective for its intended use. Read more →
De Novo classification request
A regulatory pathway for novel, low- to moderate-risk devices that have no valid predicate and would otherwise default to Class III by operation of law. A successful De Novo request allows the FDA to classify the device into Class I or Class II, generally with special controls attached, and that new classification can then serve as a predicate for later 510(k) submissions by other manufacturers. Read more →
Software as a Medical Device (SaMD)
Software intended to be used for one or more medical purposes, such as diagnosis, monitoring, or treatment guidance, without being embedded in or driving a piece of hardware, including many algorithm-based diagnostic and image analysis tools. Regulatory oversight and the applicable pathway, whether 510(k), De Novo, or PMA, depend on the software’s intended use and the risk it poses if it fails or provides incorrect information, not on the fact that it is software. Read more →
Real-World Evidence (RWE) in a device context
Clinical evidence about a device’s usage, benefits, or risks derived from analysis of real-world data, such as electronic health records, device registries, claims data, or patient-generated data, rather than from a traditional prospective controlled trial alone. Regulators can consider real-world evidence to support decisions such as expanding a device’s labeled indications, satisfying postmarket study requirements, or informing ongoing safety surveillance, alongside or in place of additional premarket studies where appropriate. Read more →

Venture and Company Formation

Pre-Seed Round
The earliest stage of institutional or angel financing, typically raised before a company has a finished product, revenue, or, in biotech, validated preclinical data. Proceeds are commonly used to fund initial hires, build a prototype or assay, or generate early proof-of-concept data that supports a subsequent seed raise. Structures at this stage are frequently SAFEs or convertible notes rather than priced equity rounds.
Seed Round
An early financing round that follows pre-seed and typically funds a company through key value-inflection milestones, such as building a founding team, generating initial experimental or clinical data, or reaching a stage suitable for Series A investment. Seed rounds may be structured as SAFEs, convertible notes, or priced preferred stock, and often involve a mix of angel investors and dedicated seed-stage venture funds.
Series A
Typically the first significant round of institutional venture capital financing structured as priced preferred equity, usually led by one or more venture funds after a company has demonstrated meaningful traction or data beyond the seed stage. Series A financings generally introduce more formal governance, including board seats for investors and a fuller set of preferred stock rights such as liquidation preferences and protective provisions.
SAFE (Simple Agreement for Future Equity)
An investment instrument, introduced by Y Combinator in 2013, under which an investor provides capital in exchange for the right to receive equity in a future priced financing round, rather than immediate shares or debt. A SAFE has no interest rate or maturity date and typically converts based on a valuation cap, a discount to the future round’s price, or both. Because it is not debt, a SAFE does not create a repayment obligation if a priced round never occurs.
Convertible Note
A short-term debt instrument that converts into equity, typically at the next qualified financing round, rather than being repaid in cash. Convertible notes carry an interest rate and a maturity date, and usually include a valuation cap and/or discount rate that determines the conversion price relative to the priced round. Unlike a SAFE, unconverted notes represent a debt obligation of the company.
Cap Table
A capitalization table is a ledger, often maintained as a spreadsheet or through dedicated software, that records all ownership interests in a company, including common stock, preferred stock, options, warrants, and outstanding convertible instruments such as SAFEs or notes. It shows each stakeholder’s ownership percentage on both a current and fully diluted basis and is updated with every financing, option grant, or conversion event.
Dilution
The reduction in an existing shareholder’s percentage ownership of a company that occurs when new shares are issued, such as in a financing round or upon exercise of options. Dilution does not necessarily reduce the dollar value of a shareholder’s stake, since new capital may increase the company’s overall valuation, but it does reduce the proportion of the company that shareholder owns.
Term Sheet
A document summarizing the principal proposed terms of an investment, including valuation, investment amount, security type, liquidation preference, board composition, and investor protective provisions. Most term sheets are non-binding except for specific clauses such as confidentiality and exclusivity, and they serve as the framework from which definitive legal financing documents are later drafted.
Liquidation Preference
A contractual right held by preferred stockholders entitling them to receive a specified return of capital before common stockholders receive any proceeds in a liquidation event, such as an acquisition, sale, or dissolution. Liquidation preferences are commonly expressed as a multiple of the original investment, most often 1x, and may be structured as non-participating, where preferred holders choose either the preference or conversion to common, or participating, where they receive both.
Rule 506(b) of Regulation D
A safe harbor exemption under Regulation D of the Securities Act of 1933 that allows a company to raise an unlimited amount of capital from an unlimited number of accredited investors and up to 35 non-accredited but financially sophisticated investors, without registering the offering with the SEC. It prohibits general solicitation or public advertising of the offering, meaning the company must rely on a pre-existing, substantive relationship with investors. Read more →
Rule 506(c) of Regulation D
A safe harbor exemption under Regulation D, added pursuant to the JOBS Act of 2012, that permits a company to publicly advertise and generally solicit an offering, in contrast to Rule 506(b), provided that all purchasers in the offering are accredited investors. The issuer must take reasonable steps to verify each investor’s accredited status, such as reviewing financial documentation, rather than simply relying on investor self-certification. Read more →
Accredited Investor
An individual or entity that meets income, net worth, or professional criteria defined by the SEC, qualifying them to participate in private securities offerings that are not registered under the Securities Act. Common individual thresholds relate to annual income or net worth, while entities such as banks, registered investment advisers, and certain funds qualify by their institutional status. The accredited investor standard is intended to limit unregistered offerings to investors deemed able to evaluate or bear the risk of the investment. Read more →
Technology Transfer Office (TTO)
An office within a university or research institution responsible for identifying, patenting, and commercializing inventions arising from faculty and student research. TTOs negotiate license or option agreements with existing companies or with newly formed spinouts, and typically retain an equity stake and future royalty rights on behalf of the institution in exchange for granting IP rights. Read more →
IP License or Option Agreement
A license agreement is a contract granting a company the right to use intellectual property, such as a patent, owned by another party, typically a university, in exchange for upfront fees, milestone payments, royalties, or equity. An option agreement instead grants a time-limited right to negotiate and later execute such a license, and is often used by early-stage spinouts to secure IP rights while they raise financing before committing to full license terms. Read more →
Spinout
A new, independent company formed to commercialize technology or intellectual property originally developed within a parent organization, most commonly a university or academic medical center. A spinout typically enters into a license or option agreement with the originating institution’s technology transfer office to secure rights to the underlying IP, and founders are often the inventing faculty, postdoctoral researchers, or an operator brought in to lead the company. Read more →
Runway
The length of time a company can continue operating before it exhausts its available cash, calculated by dividing the current cash balance by the average monthly net burn rate. Runway is a key metric for planning fundraising timelines, since companies typically aim to close a new financing round well before cash reserves run out.

Market and Reimbursement

Payer
A payer is the entity responsible for financing healthcare services, most commonly a private health insurer, a government program such as Medicare or Medicaid, or a self-insured employer. Payers negotiate rates with providers, set coverage policies determining which treatments and devices they will pay for, and often require evidence of clinical and economic value before granting favorable coverage. For a life-sciences startup, understanding payer priorities early shapes clinical trial design, pricing strategy, and the evidence needed at launch.
Reimbursement
Reimbursement is the payment a payer makes to a provider, hospital, or patient to cover the cost of a medical product or service that has been delivered. It depends on three separate determinations: coverage, whether the payer will pay for the item at all, coding, whether an accurate billing code exists to describe it, and payment, the specific rate assigned. A product with strong clinical data can still fail commercially without a clear reimbursement pathway, which is why payer strategy is typically developed alongside clinical development rather than after approval.
CPT code
A CPT, or Current Procedural Terminology, code is a five-character code maintained by the American Medical Association that identifies a specific medical, surgical, or diagnostic service for billing purposes in the United States. Most codes are purely numeric, while a smaller set of codes used for performance tracking or emerging technologies include a letter. Providers submit CPT codes on claims to payers, who use them to determine coverage and set payment amounts. New diagnostics, devices, or procedures often need a new or revised CPT code, or must temporarily bill under a less specific existing code, which can materially affect adoption and revenue during early commercialization. Read more →
Prior authorization
Prior authorization is a requirement imposed by a payer that a provider obtain approval before delivering a specific treatment, test, or procedure in order for it to be reimbursed. Payers use it to manage cost and confirm medical necessity against clinical criteria, but it adds administrative burden and can delay patient access. Startups commercializing a new drug, device, or diagnostic often need to anticipate prior authorization requirements and build supporting documentation into their go-to-market plan.
Value-based care
Value-based care is a payment and care-delivery model in which providers are reimbursed based on patient outcomes and quality of care rather than solely on the volume of services performed, as in traditional fee-for-service arrangements. Arrangements can include shared savings, bundled payments for an episode of care, or penalties tied to readmissions and complications. The model creates an incentive for technologies that demonstrably improve outcomes or reduce downstream costs, a factor payers and health systems weigh when evaluating new products.
Total addressable market (TAM)
Total addressable market, or TAM, is an estimate of the total revenue opportunity available to a product or company if it achieved complete market share within its defined market. In healthcare, a credible TAM estimate typically starts from an eligible patient or procedure population and works through realistic assumptions about diagnosis rates, treatment rates, pricing, and reimbursement, rather than citing a large disease prevalence figure alone. Investors scrutinize how a TAM is constructed, since overly broad or top-down estimates can obscure a much smaller, realistically serviceable market.
Standard of care
Standard of care refers to the treatment or diagnostic approach currently accepted by the medical community, often reflected in clinical practice guidelines, as appropriate for a given condition. It serves as the benchmark against which new therapies and devices are typically compared in clinical trials and by payers deciding on coverage. A new product’s ability to improve upon, or at least match at lower cost, the existing standard of care is central to both its regulatory and commercial case. Read more →
Key opinion leader (KOL)
A key opinion leader, or KOL, is a physician, researcher, or other expert whose clinical reputation and publications give them significant influence over how peers and institutions view a disease area, technology, or treatment approach. Companies engage KOLs for guidance on clinical trial design, for independent feedback on a product’s positioning, and for support with adoption once a product reaches the market. Because KOL relationships can shape both scientific credibility and commercial uptake, they are often cultivated well before a product’s launch.
← Knowledge Hub Readiness check → Work with us →